Use and Costs of P2Y12 Inhibitors After Acute Myocardial Infarction

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Brigham and Women's Hospital
Study ID
NCT07610577
Status
Active Not Recruiting

Conditions

  • Acute Myocardial Infarction (AMI)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Clopidogrel — DRUG
    Initiation of clopidogrel in healthcare claims is used as the exposure.
  • Prasugrel — DRUG
    Initiation of prasugrel in healthcare claims is used as the exposure.
  • Ticagrelor — DRUG
    Initiation of ticagrelor in healthcare claims is used as the exposure.

Study Details

This study aims to describe temporal trends in the use and costs of clopidogrel, ticagrelor, and prasugrel in Germany and the United States.

Key Dates

Start date
Nov 1, 2025
Status verified
Jun 2026
Primary completion
May 31, 2026
Completion
May 31, 2026

Study Design

Enrollment
377,753 participants (actual)

Arms

  • Arm: Initiators of clopidogrel
    Exposure group
  • Arm: Initiators of prasugrel
    Exposure group
  • Arm: Initiators of ticagrelor
    Exposure group

Primary Outcome Measure

Population-level trends in age- and sex-standardized proportions of clopidogrel, ticagrelor, and prasugrel initiators over time [ Time Frame: 2011 to 2024 ]

Locations (1)

FacilityCityStateZIPSite coordinators
Brigham and Women's HospitalBostonMassachusetts02120-

Find similar trials in Boston, MA

By research site
Brigham and Women's Hospital· Boston, MA

Related Studies